{
  "trial_id": "NCT04661826",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Patients of both sexes aged > 18 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Cytological or histological diagnosis of bladder cancer",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Multiple primary or recurrent Ta G1-G2 papillary cancer",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG Performance Status 0 to 1",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Adequate bone marrow function: neutrophils \u22651.5 103/mL",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Hb \u2265 10 g/dL",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Written informed consent",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Willing and able to comply with the protocol for the duration of the study",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Hypersensitivity to Paclitaxel or one of its constituents",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "T1 papillary cancer or muscle-invasive disease (T2-T4) ",
      "label": "triggers",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has metastatic papillary thyroid cancer and has undergone XRT, which may be a contraindication for intravesical therapy.",
  "_meta": {
    "topic_id": "11",
    "trial_id": "NCT04661826",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}